BioPharma-Reporter

For over 8 years, William Reed’s BioPharma-Reporter has stood out as the top online news platform for the biopharma sector. Our digital-first approach allows us to deliver valuable insights and comprehensive information that can assist your business in thriving. BioPharma-Reporter provides complete coverage of the bioprocessing landscape, catering to biopharma professionals with news centered on clinical trials, the commercial development, and production of large molecule drugs, vaccines, live biotherapeutics, and advanced therapeutics. We uphold exceptional editorial standards and share meaningful content through various channels, ensuring it reaches the right audience, no matter where they are.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#3329125

United States

#1546970

Health/Biotechnology and Pharmaceuticals

#1453

Traffic sources

Monthly visitors

Articles

Inhibikase pauses development of Parkinson’s drug

2 months ago | biopharma-reporter.com | Helen Albert

Inhibikase Therapeutics announced results from a Phase 2 trial of its Parkinson’s disease drug, risvodetinib, a selective inhibitor of the non-receptor Abelson tyrosine kinases, in a filing to the US Securities and Exchange Commission (SEC) this week. While the drug met the trial endpoint for safety and tolerability, it did not significantly improve symptoms in people with Parkinson’s disease and the company said it will now pause development of the drug to focus on its other pipeline candidates.
Atalanta Therapeutics raises $97 million to advance RNAi therapies for CNS disorders

2 months ago | biopharma-reporter.com | Larissa Warneck-Silvestrin

The U.S. biotech company Atalanta Therapeutics announced this week that it has raised $97 million in an oversubscribed Series B financing round led by the Swedish investment organization EQT Life Sciences and co-led by Sanofi Ventures and with participation from others. The financing will support the Phase 1 clinical development of two of Atalanta’s investigational RNA interference (RNAi) therapies for a specific form of epilepsy known as KCTN1-related epilepsy and Huntington’s disease.
Akero Therapeutics succeeds with MASH liver treatment at phase 2

2 months ago | biopharma-reporter.com | Helen Albert

Akero Therapeutics announced statistically significant results from a Phase 2b trial of its lead therapeutic candidate efruxifermin (EFX) this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed compensated cirrhosis due to MASH. A 96-week analysis of data showed the metabolic dysfunction-associated steatohepatitis (MASH) treatment was effective, after an earlier analysis was unclear.
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3

2 months ago | biopharma-reporter.com | Larissa Warneck-Silvestrin

The Swiss pharma giant Roche announced yesterday that the first approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), Elevidys, demonstrated statistically significant improvements in motor function in patients with DMD two years after treatment.
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial

Jan 23, 2025 | biopharma-reporter.com | Helen Albert

Amylyx Pharmaceuticals has developed an ASO called AMX0114 designed to target the calpain-2 (CAPN2) protein. This protein is involved in neurofilament biology and plays an important role in degeneration of neuronal axons, which is a key feature of ALS. AMX0114 inhibits CAPN2 and results from preclinical studies suggest that this therapy helps stop the degeneration of axons and improves neurological symptoms of ALS.
Viralgen and Axovia collaborate to manufacture gene therapy for rare disease vision loss

Jan 23, 2025 | biopharma-reporter.com | Larissa Warneck-Silvestrin

The Spanish contract development and manufacturing organization (CDMO) Viralgen and UK gene therapy developer Axovia Therapeutics announced yesterday that they have joined forces to boost the development and manufacturing of an investigational gene therapy to treat retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS). BBS is a rare genetic disease that affects different organs in the body.
Neogap Therapeutics move into clinic with personalized cancer immunotherapy

Jan 21, 2025 | biopharma-reporter.com | Helen Albert

Neogap is developing a personalized Tumor Trained Lymphocyte (pTTL) therapy, which takes the patients’ own T cells and enhances them to enable them to fight cancer better. It does this by training a patient’s T cells to recognize neoantigens, which are specific to a patient’s tumor.
Nanobiotix’s radiotherapy-activated nanoparticle cancer candidate enters Phase 2

Jan 21, 2025 | biopharma-reporter.com | Larissa Warneck-Silvestrin

The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating its potentially first-in-class radiotherapy-activated nanoparticle candidate, JNJ-1900 (NBTXR3).
Umoja raises $100 million to boost its CAR-T cell gene therapy pipeline

Jan 16, 2025 | biopharma-reporter.com | Larissa Warneck-Silvestrin

The U.S. biotech company Umoja Biopharma announced this week that it has raised $100 million in a Series C financing round co-led by Double Point Ventures and DCVC Bio, and supported by other new and existing investors. The proceeds will support the clinical development of Umoja’s in vivo CAR-T cell therapies –including its lead program UB-VV400 –for the treatment of cancer and autoimmune diseases.
Hinge Bio raises $30 million to progress B cell lupus therapy

Jan 16, 2025 | biopharma-reporter.com | Helen Albert

Hinge Bio is based in Burlingame, California and has developed a platform technology called GEM-DIMER, which aims to deplete B cells and reset the immune system in B-cell mediated autoimmune conditions such as systemic lupus erythematosus. The $30 million Series A fundraise was led by American hedge fund Point72. Ridgeback Capital, InVivium Capital, Lightswitch Capital and others also contributed to the fundraise.